Review by Forecast to 2032aa

Market overview

The global <u>organ transplantation market share</u>, asper the study conducted by Market Research Future(MRFR), is expected to reach at a compound annualgrowth rate of 9.5% during the forecast period of 2023 to 2032.

Organ transplantation involves the process ofreplacing the diseased and damaged organ of an individual with a healthy organ. It is one of the greatadvancements in the modern healthcare landscape. This medical procedure has evolved and advancedover the years, thereby enhancing the clinical effectivity of the same. Organs are donated by eithersome living donor or it is harvested from the brain-dead organ donors. Dysfunction of the organ caused due to diseases like cancer, severe injuries, failure of the organ, and due to genetic disorders require the need for organ transplant procedures. Organssuch as heart, liver, lungs, kidney, and many morecan be transplanted through this procedure.

The transplantation process is carried out primarilywith the brain-dead patient whose other organs arein a healthy state and can be used to save the life ofanother person. An increasing number of organtransplantation surgeries undertaken globally is one of the major drivers of the organ transplantationmarket. Increasing prevalence of chronic diseases, advancements in technology, changing lifestyle ofindividuals, and the rising aging population are some of the other key factors influencing the growth of the global market.

Competitive Landscape

The global organ transplantation market players of various notable players TransMedic, Inc. (US), Transonic (US), Novartis International AG(Switzerland), OrganOX Limited (UK), F. Hoffmann-La Roche Ltd. (Switzerland), Terumo MedicalCorporation (US), Preservation Solutions, Inc. (US), Transplant Biomedical (UK), AccordHealthcare GmbH (Spain), Astellas Pharma, Inc(Japan), Pfizer, Inc. (US), Veloxis Pharmaceuticals A/S (Denmark), Bio Med Pvt. Ltd. (US), GlaxoSmithKline Plc. (UK), Sanofi (France), and others.

Market Segmentation

The global <u>organ transplantation market outlook</u> segmentation is done as per the following dynamics: type. End-users, products, and treatment.

By type, the market comprises of lungs, heart, liver, kidney, and others.

By products, the market segments into tissue products, organ preservation solutions, transplant diagnostics, and others.



By type of treatment, the market includes immunosuppressant, analgesic, and other. Immunosuppressant is narrowed down into mTOR inhibitor, calcineurin inhibitors, steroids, antiproliferative agents, and other. Whereas calcineurin inhibitors are divided into tacrolimus and cyclosporine. And, mTOR inhibitor is broken down into sirolimus and everolimus.

By type of transplant, the market includes allograft, xenograft, autograft, allotransplantation, xenotransplantation, and others.

By end users, the market comprises transplant centers, hospitals, and others.